Ultrasound-Guided Intra-Articular vs Gluteal Intramuscular Corticosteroid Injection for Frozen Shoulder

Last updated: May 29, 2026
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Overall Status: Active - Recruiting

Phase

4

Condition

Bursitis

Treatment

Compound betamethasone injection (dorsogluteal intramuscular)

Standardized home-based shoulder rehabilitation exercise program

0.9% sodium chloride injection (dorsogluteal intramuscular placebo)

Clinical Study ID

NCT07416916
2024-0434
  • Ages 18-65
  • All Genders

Study Summary

The goal of this clinical trial is to determine if a gluteal muscle injection of compound betamethasone is as effective as an ultrasound-guided intra-articular injection in treating frozen shoulder (adhesive capsulitis) in adults aged 18 to 65. The main questions it aims to answer are:

  • Is gluteal injection as effective as ultrasound-guided intra-articular injection for improving shoulder function and reducing pain?

  • What are the side effects of each treatment method? Researchers will compare these two injection methods.

Participants will:

  • Receive one injection at baseline and will be followed up for 12 weeks

  • Complete shoulder function assessments

  • Perform home rehabilitation exercises

Eligibility Criteria

Inclusion

Inclusion Criteria (all must be met):

  1. Symptom duration ≤9 months; clinically diagnosed unilateral primary (idiopathic) frozen shoulder (including diabetes-associated frozen shoulder).

  2. Age 18 to 65 years.

  3. Worst shoulder pain in the past 24 hours (NRS-WP, 0-10) ≥4.

  4. Passive range of motion (ROM) limitation of the affected shoulder: compared with the contralateral normal shoulder, a decrease of ≥30° in at least two of the following three directions: forward flexion, abduction, and external rotation with the arm at the side.

  5. Radiographic exclusion of other shoulder pathology: Affected-shoulder anteroposterior (AP) radiograph excludes glenohumeral osteoarthritis, calcific tendinopathy, and other structural abnormalities; and axillary view and/or scapular Y (outlet) or transthoracic view excludes glenohumeral dislocation.

Exclusion Criteria (any of the following):

  1. Secondary frozen shoulder due to thyroid disease, cardiovascular disease, stroke, radiotherapy, prior neurosurgical or breast surgery, etc. (diabetes excluded from this item); or frozen shoulder secondary to major shoulder trauma requiring medical care (e.g., fracture, dislocation, rotator cuff tear).

  2. Confirmed or highly suspected full-thickness or massive rotator cuff tear causing functional pseudoparalysis (e.g., positive Jobe test with marked strength loss).

  3. Local infection of the affected shoulder or any contraindication to shoulder injection (e.g., uncorrected bleeding risk/coagulopathy).

  4. Contraindication to corticosteroid therapy (e.g., poorly controlled diabetes, systemic infection).

  5. Prior manipulation under anesthesia, arthroscopic capsular release, or open surgical release for frozen shoulder on the affected shoulder.

  6. Any corticosteroid treatment via any route within the past 3 months (including shoulder injection).

  7. Requires long-term or intermittent corticosteroid use for other conditions (e.g., autoimmune disease such as rheumatoid arthritis, acute asthma exacerbations).

  8. Bilateral frozen shoulder, or contralateral history of frozen shoulder not yet fully recovered.

  9. Conditions significantly affecting upper-limb function assessment or ability to perform rehabilitation (e.g., marked limb disability).

  10. Pregnant or breastfeeding.

  11. Lacks the cognitive ability to comply with study procedures.

  12. Does not reside in the region served by the participating hospital(s) (anticipated inability to complete follow-up).

  13. Compensation claims (e.g., work-related injury, traffic accident) or ongoing legal disputes/litigation.

Study Design

Total Participants: 528
Treatment Group(s): 5
Primary Treatment: Compound betamethasone injection (dorsogluteal intramuscular)
Phase: 4
Study Start date:
February 23, 2026
Estimated Completion Date:
January 31, 2031

Connect with a study center

  • Yangpu District Central Hospital of Shanghai

    Shanghai, Shanghai Municipality 200082
    China

    Site Not Available

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    Hangzhou, Zhejiang 310009
    China

    Active - Recruiting

  • The First People's Hospital of Linping District, Hangzhou

    Hangzhou, Zhejiang 311199
    China

    Site Not Available

  • The Third Affiliated Hospital of Zhejiang Chinese Medical University

    Hangzhou, Zhejiang 310000
    China

    Site Not Available

  • Huzhou Central Hospital

    Huzhou, Zhejiang 313000
    China

    Active - Recruiting

  • Pujiang People's Hospital

    Jinhua, Zhejiang 322200
    China

    Site Not Available

  • First Affiliated Hospital of Ningbo University

    Ningbo, Zhejiang 315020
    China

    Active - Recruiting

  • Xiangshan County Traditional Chinese Medicine Hospital Healthcare Group

    Ningbo, Zhejiang 315799
    China

    Site Not Available

  • Shengzhou People's Hospital

    Shanhu, Zhejiang 312400
    China

    Site Not Available

  • The First People's Hospital of Linping District, Hangzhou

    Hangzhou 1808926, Zhejiang 1784764 311199
    China

    Site Not Available

  • The Third Affiliated Hospital of Zhejiang Chinese Medical University

    Hangzhou 1808926, Zhejiang 1784764 310000
    China

    Site Not Available

  • Xiangshan County Traditional Chinese Medicine Hospital Healthcare Group

    Ningbo 1799397, Zhejiang 1784764 315799
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.